• Incyte Corp., of Wilmington, Del., posted net product revenues from sales of myelofibrosis drug Jakafi (ruxolitinib) totaling $48.3 million for the first quarter, with product royalties from sales of the drug, marketed as Jakavi outside the U.S. by partner Novartis AG, of Basel, Switzerland, totaling $5.9 million.